Equities

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)53.88
  • Today's Change1.11 / 2.10%
  • Shares traded933.93k
  • 1 Year change+83.33%
  • Beta0.6426
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy4
Outperform9
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 13 analysts offering 12 month price targets for Crinetics Pharmaceuticals Inc have a median target of 70.00, with a high estimate of 97.00 and a low estimate of 48.00. The median estimate represents a 29.92% increase from the last price of 53.88.
High80.0%97.00
Med29.9%70.00
Low-10.9%48.00

Earnings history & estimates in USD

On Aug 08, 2024, Crinetics Pharmaceuticals Inc reported 2nd quarter 2024 losses of -0.94 per share.
The next earnings announcement is expected on Nov 05, 2024.
Average growth rate-0.24%
Crinetics Pharmaceuticals Inc reported annual 2023 losses of -3.69 per share on Feb 28, 2024.
Average growth rate-15.28%
More ▼

Revenue history & estimates in USD

Crinetics Pharmaceuticals, Inc. had 2nd quarter 2024 revenues of 399.00k. This missed the 510.00k consensus estimate of the 10 analysts following the company. This was 85.11% below the prior year's 2nd quarter results.
Average growth rate-67.55%
Crinetics Pharmaceuticals, Inc. had revenues for the full year 2023 of 4.01m. This was 15.28% below the prior year's results.
Average growth rate+412.10%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.